In scientific studies nicotinamide mononucleotide (NMN) usually studied in doses between approx 250 mg and 900 mg per day. Some studies also analyze higher amounts up to approx 1000 mg per day, depending on the study design and the biological markers researchers want to measure.
Researchers study NMN especially in relation to it NAD⁺ metabolism, because this molecule is a precursor of NAD⁺ (nicotinamide adenine dinucleotide), a coenzyme involved in many cellular processes.
Research results from different NMN studies cannot always be directly compared. This is because studies often have a different research design.
For example, studies can focus on:
In addition, studies may differ due to factors such as:
Due to these variations, results from individual studies cannot always be directly compared.
The table below provides an overview of dosages that are regularly investigated in clinical studies.
| Dosage | Context in studies |
|---|---|
| 250mg | One of the most commonly used dosages in human clinical trials. Often investigated to analyze changes in NAD⁺ metabolism. |
| 300mg | Comparable to 250 mg and used in studies with healthy adults and elderly subjects. |
| 500 mg | Medium-high research dose used in some studies for more extensive metabolic measurements. |
| 600 mg | Used in some studies when researchers analyze changes in NAD⁺-related markers. |
| 900 mg | Occurs in some clinical studies as a higher research dose. |
| 1000 mg | Sometimes investigated as an upper limit of doses in clinical protocols. |
Within the research field surrounding NAD⁺ metabolism, NMN is referred to as: NAD Supplement also discussed by scientists researching aging biology.
So it has David Sinclair, professor of genetics at Harvard Medical School, stated in several interviews and podcasts that he personally approx 1000 mg NMN per day used as part of his daily routine. This personal routine is often mentioned in discussions of longevity research.
In scientific studies, NMN can be administered in several forms, including:
Capsules are often used in clinical trials because they make it easier to standardize dosages and conduct placebo-controlled studies. In other research designs, researchers use powder to weigh very accurate quantities. Because the differences between capsules and powders regularly raise questions, this is discussed in more detail in a separate article NMN powder vs capsules.
In clinical studies nicotinamide mononucleotide (NMN) usually studied in doses between approx 250 mg and 900 mg per day. Some research designs also analyze higher quantities up to approx 1000 mg per day.
Studies use different dosages because they have different research goals. Some studies focus on changes in NAD⁺ levels, while other studies look at metabolic markers or pharmacokinetic properties of the substance.
In many human studies, dosages are rounded out 250 mg to 500 mg per day investigated. Some studies also use higher amounts to analyze changes in biological markers.
In scientific studies, NMN can be both and capsule as in powder form are used. Capsules are often used in clinical trials with participants, while powder form is regularly used when researchers want to weigh very precise quantities.
Within the research field surrounding NAD⁺ metabolism, NMN is also discussed by scientists researching aging biology. For example, Harvard researcher David Sinclair has indicated in interviews that he personally approx 1000 mg NMN per day used as part of his daily routine.
